We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.07% | 97.27 | 97.91 | 97.07 | 97.75 | 1,045,674 | 01:00:00 |
From May 2022 to May 2024
By Maitane Sardon
Novartis AG said that two children who received its gene therapy for a neuromuscular disease died after the treatment.
The patients developed acute liver failure about five to six weeks after being administered the gene therapy, Zolgensma, which is used to treat spinal muscular atrophy, a muscle-wasting condition.
"While acute liver failure is a known adverse event, these are the first fatal cases of acute liver failure," the Swiss pharma major said in an emailed statement Friday.
Novartis said the children had also received corticosteroids, which are used alongside Zolgensma to prevent complications that can lead to severe liver damage.
The deaths occurred in Russia and Kazakhstan, Novartis said.
"Pending health authority review and approval, the Zolgensma label will be updated to inform prescribers that fatal acute liver failure has been reported," Novartis said.
Write to Maitane Sardon at maitane.sardon@wsj.com
(END) Dow Jones Newswires
August 12, 2022 05:20 ET (09:20 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
